Pharvaris (NASDAQ:PHVS) Shares Up 5.8% – Here’s Why
by Michael Walen · The Markets DailyShares of Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) traded up 5.8% on Friday . The company traded as high as $39.94 and last traded at $39.69. Approximately 130,515 shares were traded during trading, a decline of 66% from the average session volume of 384,517 shares. The stock had previously closed at $37.51.
Trending Headlines about Pharvaris
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the pivotal Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the trial met its primary and secondary endpoints. The company plans to begin regulatory submissions in the first half of 2027. CHAPTER-3 trial report
- Positive Sentiment: The results strengthen Pharvaris’ competitive position in HAE because the company is developing oral therapies for both prophylactic and on-demand use. Analysts believe oral convenience, combined with the efficacy data, could help Pharvaris gain market share. RBC HAE market-share analysis
- Positive Sentiment: Analyst sentiment remains favorable. Leerink Partners initiated or reiterated a Buy-equivalent rating with a $65 price target, while RBC Capital maintained its Buy/Outperform view and raised its target to $62. Citizens JMP also increased its target to $79 and maintained Market Outperform. HC Wainwright reaffirmed Buy with a $60 target, and Wedbush maintained Outperform. Leerink Partners rating
- Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition from established HAE therapies. Pharvaris is still a clinical-stage, loss-making company, so future valuation will remain sensitive to clinical and regulatory developments.
- Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest insider-selling overhang, although it does not alter the positive clinical results. Pharvaris insider sale
Analyst Ratings Changes
Several research firms have commented on PHVS. Guggenheim boosted their target price on Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday. Leerink Partners upped their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday. UBS Group set a $79.00 price objective on shares of Pharvaris in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a report on Tuesday. Finally, Royal Bank Of Canada upped their target price on shares of Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $59.50.
Get Our Latest Research Report on PHVS
Pharvaris Stock Up 2.6%
The stock has a market capitalization of $2.52 billion, a P/E ratio of -12.60 and a beta of -2.33. The business has a fifty day moving average price of $35.01 and a 200-day moving average price of $31.34.
Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, equities analysts expect that Pharvaris N.V. will post -3.1 earnings per share for the current fiscal year.
Insider Activity at Pharvaris
In related news, insider Anne Lesage sold 30,703 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the transaction, the insider owned 93,969 shares in the company, valued at $3,334,959.81. This represents a 24.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Peng Lu sold 15,000 shares of Pharvaris stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total transaction of $610,200.00. Following the completion of the sale, the president directly owned 65,179 shares of the company’s stock, valued at approximately $2,651,481.72. This trade represents a 18.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 133,655 shares of company stock valued at $4,798,202 over the last ninety days. Company insiders own 11.84% of the company’s stock.
Institutional Investors Weigh In On Pharvaris
A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System boosted its holdings in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after buying an additional 520 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Pharvaris during the second quarter worth about $41,000. Public Employees Retirement System of Ohio grew its position in shares of Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period.
About Pharvaris
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.